 Daily Mail |
UK's NICE rejects Novartis asthma drug in change of tack
Reuters Health ». LONDON | Thu Nov 8, 2012 7:06pm EST. LONDON (Reuters) – Britain's health cost-effectiveness watchdog NICE plans to recommend against the use of Novartis's severe asthma drug Xolair, or omalizumab, after earlier endorsing it for adults only. Now English asthma patients are denied life-changing drug offered to Scots Asthma drug life changing: swimmer |
View full post on asthma – Google News